[go: up one dir, main page]

CO2022004335A2 - Variantes del cnp y sus conjugados - Google Patents

Variantes del cnp y sus conjugados

Info

Publication number
CO2022004335A2
CO2022004335A2 CONC2022/0004335A CO2022004335A CO2022004335A2 CO 2022004335 A2 CO2022004335 A2 CO 2022004335A2 CO 2022004335 A CO2022004335 A CO 2022004335A CO 2022004335 A2 CO2022004335 A2 CO 2022004335A2
Authority
CO
Colombia
Prior art keywords
conjugates
cnp variants
cnp
variants
present disclosure
Prior art date
Application number
CONC2022/0004335A
Other languages
English (en)
Inventor
Daniel J Wendt
Geoffrey Berguig
Karol Estrada
Jonathan Lebowitz
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of CO2022004335A2 publication Critical patent/CO2022004335A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

RESUMEN La presente descripción, se refiere, en general, a variantes estables del péptido natriurético de tipo C (CNP) y sus usos para tratar trastornos relacionados con los huesos.
CONC2022/0004335A 2019-09-16 2022-04-05 Variantes del cnp y sus conjugados CO2022004335A2 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962901093P 2019-09-16 2019-09-16
US201962935050P 2019-11-13 2019-11-13
US202062963350P 2020-01-20 2020-01-20
US202062964852P 2020-01-23 2020-01-23
US202063038667P 2020-06-12 2020-06-12
PCT/US2020/051100 WO2021055497A1 (en) 2019-09-16 2020-09-16 Cnp variants and conjugates thereof

Publications (1)

Publication Number Publication Date
CO2022004335A2 true CO2022004335A2 (es) 2022-08-30

Family

ID=72709850

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0004335A CO2022004335A2 (es) 2019-09-16 2022-04-05 Variantes del cnp y sus conjugados

Country Status (15)

Country Link
US (1) US20230192799A1 (es)
EP (1) EP4031183A1 (es)
JP (1) JP2022547723A (es)
KR (1) KR20220063220A (es)
CN (1) CN114616242A (es)
AU (1) AU2020349493A1 (es)
BR (1) BR112022004697A2 (es)
CA (1) CA3153730A1 (es)
CL (1) CL2023001727A1 (es)
CO (1) CO2022004335A2 (es)
IL (1) IL291179A (es)
MX (1) MX2022003184A (es)
PE (1) PE20220488A1 (es)
TW (1) TW202124422A (es)
WO (1) WO2021055497A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024000526A (es) * 2021-07-09 2024-02-02 Biomarin Pharm Inc Variantes del peptido natriuretico tipo c para tratar la displasia esqueletica en ni?os.
AU2022407450A1 (en) 2021-12-07 2024-07-11 Biomarin Pharmaceutical Inc. CNP Therapy
AU2022413318A1 (en) 2021-12-13 2024-05-16 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
EP4452300A1 (en) * 2021-12-20 2024-10-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of analog of c-type natriuretic peptide for the treatment of fgfr-related bone repair and bone formation impairment
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
TW202419463A (zh) 2022-11-02 2024-05-16 丹麥商諾佛 儂迪克股份有限公司 Cnp化合物
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
WO2024254405A2 (en) 2023-06-07 2024-12-12 Biomarin Pharmaceutical Inc. High throughput screen for genetic variants associated with short stature

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0478797B1 (en) 1990-04-20 1995-04-12 Hisayuki Matsuo Novel physiologically active peptide originating in hog
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
KR102225470B1 (ko) * 2009-05-20 2021-03-10 바이오마린 파머수티컬 인크. 씨형 나트륨이뇨 펩티드의 변이체
PT3328416T (pt) * 2015-07-30 2024-04-10 Biomarin Pharm Inc Utilização de variantes do péptido natriurético de tipo c para tratar as displasias esqueléticas
US11413351B2 (en) * 2016-01-08 2022-08-16 Ascendis Pharma Growth Disorders A/S CNP prodrugs with carrier attachment at the ring moiety

Also Published As

Publication number Publication date
TW202124422A (zh) 2021-07-01
CA3153730A1 (en) 2021-03-25
JP2022547723A (ja) 2022-11-15
WO2021055497A1 (en) 2021-03-25
MX2022003184A (es) 2022-06-23
EP4031183A1 (en) 2022-07-27
US20230192799A1 (en) 2023-06-22
PE20220488A1 (es) 2022-04-04
AU2020349493A1 (en) 2022-04-07
CL2023001727A1 (es) 2024-01-12
IL291179A (en) 2022-05-01
KR20220063220A (ko) 2022-05-17
CN114616242A (zh) 2022-06-10
BR112022004697A2 (pt) 2022-06-14

Similar Documents

Publication Publication Date Title
CO2022004335A2 (es) Variantes del cnp y sus conjugados
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
CO2018002328A2 (es) Formulaciones que comprenden variantes de péptido natriurético de tipo c (cnp)
CL2019002132A1 (es) Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinético y sus usos.
MX2019006598A (es) Celulas asesinas naturales modificadas geneticamente y sus usos.
CL2019001129A1 (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y.
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
PE20210633A1 (es) CONSTRUCTOS DE ARNi PARA INHIBIR LA EXPRESION DE PNPLA3 Y METODOS DE USO DE LOS MISMOS
PE20210665A1 (es) Anticuerpos contra mica y/o micb y sus usos
MX384379B (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-fármaco.
UY37590A (es) COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR)
UY37589A (es) COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR)
MX2020004600A (es) Constructos de oligonucleotidos y usos de estos.
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
MX2019012428A (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
UY38200A (es) Conjugados de tirosina-tirosina de péptido cíclico acoplado a péptido de fusión de glp-1 y sus usos
CO2021007402A2 (es) Constructos de suministro para transcitosis y métodos relacionados
CL2020001846A1 (es) Anticuerpos pac1 y sus usos
AR122014A1 (es) Receptor de antígenos quimérico enmascarado específico para la proteína tirosina cinasa de tipo 7 (ptk7) y células inmunitarias que expresan el mismo
ECSP22003596A (es) Moduladores del receptor de nmda
AR114291A1 (es) Conjugados de péptido tirosina tirosina cíclico con péptido de fusión del péptido similar al glucagón tipo 1 (glp-1) acoplado y usos de estos
MX2021015922A (es) Proteínas quiméricas sintéticas estabilizadas y sus usos terapéuticos.
CO2024008727A2 (es) Terapia con péptido natriurético tipo c de trastornos relacionados con los huesos
AR117017A1 (es) Constructos de entrega para transcitosis y métodos relacionados
AR130935A1 (es) Compuestos de cnp